Skip to main content

Table 1 Summary of longitudinal cohorts in three West African and three East African countries selected to receive assistance by the Schistosomiasis Control Initiative for implementation of preventive chemotherapy programmes against schistosomiasis (and soil-transmitted helminthiasis)

From: Estimation of changes in the force of infection for intestinal and urogenital schistosomiasis in countries with schistosomiasis control initiative-assisted programmes

Country

Species

Cohort Size at Baseline (No. schools)

BL Year

Tx BL

FY1 Year, Numbers, (Follow-up rate), Number of schools

Tx FY1

FY2 Year, Numbers, (Follow-up rate), Number of schools

Tx FY2

FY3 Year, Numbers, (Follow-up rate), Number of schools

Tx FY3

Age-range of school cohorts at baseline

Proportion of females at BL (%)

Relevant Publications

West Africa

 

Burkina Faso

S. haematobium

1,422 (16 schools)

2004

Y

2005, 996 (70.0 %) 16 schools

N

2006, 770 (54.1 %) 16 schools

Y

2007, 564 (39.7 %) 15 schools

N

6-12

46.6

[2, 90, 91, 93]

Mali

S. mansoni & S. haematobium

3,599 (33 schools)

Mar-Jun 2004

Y

May-Jun 2005 and Apr – May 2006 1995 (55.4 %) 24 schools

Y

Mar-Apr 2006 and May-June 2007 (1511 (42.0 %) 27 schools

Y

ND

Y

7-14

49.9

[2, 26, 90, 91]

Niger

S. haematobium

1,656 (8 schools)

Oct-Nov 2004 and Mar-May 2005

Y

Oct-Dec 2005 and Mar-Apr 2006,1440 (87.0 %) 8 schools

Y

Nov-Dec 2006 and Jan-May 2007, 1193 (72.0 %) 8 schools

Y

ND

x

7,8,11

45.5

[2, 82, 90, 91, 94]

East and Southern Africa

 

Tanzania

S. mansoni & S. haematobium

3,145 (20 schools)

2005

Y

2006, 2235 (71.1 %) 19 schools

Y

-

N

2008, 1076 (34.2 %) 14 schools

N

7-12

56.9

[2, 92]

Uganda

S. mansoni

4,351 (37 schools)

2003

Y

2004, 2815 (64.7 %) 37 schools

Y

2005, 1871 (43.0 %) 37 schools

Y

2006, 1156 (26.6 %) 33 schools

Y

6-8, 11

49.1

[1, 2, 92, 95]

Zambia

S. mansoni & S. haematobium

2,689 (22 schools)

Jul-Aug 05 and May –Jun 06

Y

Sep 2006 and May-Jun 2007, 1633 (56.9 %) 21 schools

Y

-

N

-

x

7-12

53.4

[2, 92]

  1. BL baseline, Tx treatment round, FY1 follow-up year 1, FY2 follow-up year 2, FY3 follow-up year 3, Y treatment received, N treatment not received, ND not done